Bio Preventive Medicine Corp.

NT$21.80As of Sun 8 Nov 2026, 12:00 UTC

TPEx:6810Healthcare

Country Taiwan

PE (Fwd) —

TSR 5Y CAGR (2.40%)

Div yield —

ROE (27.96%)

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM (6.24%)

Mkt cap NT$1.078B

ROIC (62.90%)

SE Grade™

—

Value

Quality

Moat

1Y Price

Reference

NT$23

4.19%

(83.97%)

Price above Reference Value

TTM

FYE 31 Dec TWD

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

2.627

RevenueNT$M

—

2.177

1.208

12.30

2.627

2.228

6.46%

—

(78.64)

Revenue growth%

—

(44.51)

917.96

(78.64)

(15.20)

(44.51)

—

87.70

Gross margin%

—

89.48

89.65

96.42

87.70

87.72

89.57

—

(3832.05)

Operating margin%

—

(3252.69)

(6006.95)

(697.44)

(3832.05)

(100.00)

(3542.37)

—

(3800.80)

Net margin%

—

(3258.61)

(6066.64)

(712.04)

(3800.80)

(100.00)

(3529.71)

—

P/E ratio (avg)x

—

EV/EBITx

—

(8.97)

FCF yield (avg)%

—

(14.75)

(4.90)

(5.36)

(7.38)

(0.21)

(6.37)

—

(3679.10)

FCF margin%

—

(9521.73)

(5435.10)

(549.46)

(3679.10)

(100.00)

(4557.10)

—

0.968

FCF / Net incomex

—

2.922

0.896

0.772

0.968

—

0.932

—

(62.90)

ROIC%

—

(39.23)

(41.20)

(51.44)

(62.90)

(1.41)

(46.32)

—

(27.96)

Return on equity%

—

(50.48)

(52.26)

(32.01)

(27.96)

(0.73)

(41.25)

—

(23.48)

Return on assets%

—

(25.97)

(27.69)

(16.53)

(23.48)

(0.53)

(24.73)

—

(2.02)

EPSNT$

—

(2.03)

(2.16)

(2.47)

(2.02)

(0.05)

—

18.10

EPS growth%

—

(6.49)

(14.00)

18.10

97.77

(6.49)

—

6.21

Bookvalue per shNT$

—

4.02

4.13

11.46

6.21

6.17

15.58%

—

(1.95)

FCF per shareNT$

—

(5.93)

(1.94)

(1.90)

(1.95)

(0.05)

—

Dividend per shNT$

—

Div yield (avg)%

—

Payout ratio%

—

49.45

Shares (diluted)M

—

34.93

33.88

35.51

49.45

◌49.45

12.29%

—

(39.24)

Buyback yield%

—

2.99

(4.81)

(39.24)

◌—

(4.81)

—

0.331

D/E ratiox

—

0.867

0.811

0.264

0.331

0.333

0.571

—

0.929

Enterprise valueNT$B

—

1.445

1.371

1.016

1.160

0.931

(7.06%)

—

96.33

LT debtNT$M

—

113.4

106.2

101.7

96.33

(5.29%)

—

Peers (US$30.17M)

Cap (US$)

LabTurbo Biotech…

30.51M

—

Enimmune Corporation

29.85M

—

Level Biotechnology…

29.70M

15.30x

Lyka Labs Limited

30.27M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(37.94)

(33.17)

Own earn%

—

Sh yield%

(39.24)

(4.81)

Owners

Insiders/Inst%

5.29

1.61

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

1/3

EPS growth years

1/3

Dividend streakyrs

Op margin range%

−6007–−697

$1 testx

—

Incr. ROIC%

—

Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management.

Growth vs revenue

Latest

Trend

3Y CAGR

Rel growth

Revenue

NT$2.627M

6.46%

1.00×

Cost of revenue

NT$0.323M

12.15%

1.17×

Operating expenses

NT$103.0M

12.27%

1.17×

Asset mix

Trend

Cash and investments

58.93%

Other

41.07%

Reinvestment returns

No breakdown available